Epithalon is the flagship product of a four-decade Soviet and Russian research program into short tissue-specific peptides claimed to reset aging biology, including telomerase activation and measurable mortality reduction in a 266-patient cohort. The mechanism is genuinely interesting. The evidence supporting it has a single-institution problem Western science hasn't been able to get past for over twenty years.
The Human Machine
-
Epithalon and the Khavinson Bioregulators -
Follistatin, ACE-031, and the Myostatin Inhibitor Gene-Doping Frontier Knock out one gene and mice, cattle, whippets, and at least one documented human infant all put on twice the normal muscle mass. Myostatin inhibition is one of the most reproducible dramatic phenotypes in mammalian biology, which is exactly why it became a grey-market peptide category — follistatin and ACE-031 chief among them. What the animal data actually shows, why the one drug that matched it in a human trial got shut down by nosebleeds, and why "follistatin-344" in a vial is not the same intervention as the gene therapy that generated the exciting numbers.
-
GHK-Cu: The Copper Peptide and the Injectable Leap GHK-Cu is a rare grey-market peptide with genuinely strong topical evidence behind it — decades of published dermatology research and real randomized trials on skin and wound healing. The injectable, systemic anti-aging version sold today is a different claim entirely, resting on animal data and gene-expression studies that were never designed to prove what the injection ads imply.
-
IGF-1 LR3 and PEG-MGF: The Untested Growth Factors Two engineered variants of the same growth-factor system promise bodybuilders an anabolic signal potent enough to override normal growth regulation and a "muscle memory" molecule that reactivates dormant stem cells. The underlying cell biology is real and well-published. What's missing is any completed human trial for either compound's marketed purpose — and the one FDA-approved, correctly-dosed relative of this pathway carries a black-box hypoglycemia warning that grey-market users are self-administering around without the monitoring it was built for.
-
MOTS-c and the Mitochondrial-Derived Peptide Frontier Mitochondrial DNA was supposed to be a parts list for the cell's power plant, not a source of circulating hormones. MOTS-c broke that assumption in 2015, and a decade of exercise-mimetic hype has since outrun the one human trial that actually tested it. This is the mechanism, the mouse data everyone cites, the genetics story that didn't survive replication, and the grey-market vial trade running ahead of a peptide the FDA is only now getting around to reviewing.
-
Semax and Selank: The Russian Neuropeptide School Semax and Selank are unusual entries in the grey-market peptide catalog: they aren't speculative research chemicals but actual approved drugs in Russia, on the country's List of Vital and Essential Drugs, prescribed for decades. Both come from the same institute, use the same molecular design trick, and carry a real mechanistic story around BDNF and neurotransmitter modulation. The catch is that almost the entire evidence base lives in Russian-language journals and small non-randomized trials that Western medicine has never independently replicated — and "approved in Russia" is a weaker credential than the marketing makes it sound.
-
TB-500 and the Thymosin Beta-4 Evidence Gap TB-500 is sold across grey-market vendors as a fast-track tissue-repair peptide, built on real cell biology involving actin sequestration and angiogenesis. It also entered human wellness circles by way of a veterinary doping scandal, not a clinical development program, and as of 2026 has never completed a published human trial for any indication.
-
Antimicrobial Peptides: The Innate Immune System's Own Antibiotics Long before penicillin, animals, plants, and fungi were making their own antibiotics — short cationic peptides that rupture microbial membranes by physics rather than by inhibiting a single enzyme. How human defensins and cathelicidins actually kill bacteria, why the polymyxin antibiotics already prove the mechanism works in the clinic, and why turning that mechanism into a marketable drug has been so much harder than the biology alone would suggest.
-
AOD-9604 and the GH Fragment Marketing Gap AOD-9604 is a growth-hormone-derived fragment peptide sold widely today as a fat-loss and joint-repair compound, built on a genuinely clever piece of 1990s endocrinology — a lipolytic domain isolated from the rest of the GH molecule. It also failed its own Phase 2b obesity trial in 2007. Both facts matter, and only one of them shows up in the marketing.
-
BPC-157 and the Research-Peptide Gray Market BPC-157 has a real, unusually stable structure and a genuinely striking animal-trial record — and almost no controlled human data, an FDA compounding ban, and a supply chain that self-injects with no regulatory floor under it. Here's what the evidence actually supports.
-
CagriSema and the Amylin Comeback Pairing a long-acting amylin analog with semaglutide was supposed to be Novo Nordisk's answer to tirzepatide. The REDEFINE program shows a real, large effect — and a head-to-head trial showing it still isn't quite enough.
-
Collagen Peptides: What the Evidence Actually Says Collagen supplements get digested like any other protein, which should mean they can't reach your skin intact — except a specific dipeptide reliably does. The mechanism is real and measurable. Whether it translates into a benefit worth paying for depends heavily on who funded the trial you're reading.
-
GHRH and GHRP Secretagogues: Asking the Pituitary Instead of Replacing It Sermorelin, ipamorelin, and their relatives don't put growth hormone into your body — they ask your pituitary to make more of its own, through two distinct receptor pathways that leave the body's natural feedback loop intact. That distinction is real, but it doesn't make the anti-aging marketing built on top of it true.
-
GLP-1 Agonists, Honestly Semaglutide and tirzepatide are real drugs built on real incretin physiology, not a fad and not magic. How a gut hormone with a two-minute half-life became a weekly injection with double-digit percentage weight-loss effect sizes, what the honest side-effect and muscle-loss data actually show, and what happens metabolically when you stop taking it.
-
GLP-2 Analogs for Short Bowel While GLP-1 dominates headlines for appetite suppression, its sibling hormone GLP-2 does the opposite job entirely: growing intestinal tissue back. Apraglutide and glepaglutide are the next generation of a small, rare-disease drug class built on that trophic signal.
-
How Peptide Drugs Are Made Every peptide drug, from a nine-residue hormone analog to a 39-residue molecule like tirzepatide, is built the same fundamental way chemist Bruce Merrifield worked out in 1963: one amino acid at a time, anchored to a solid resin bead. How solid-phase peptide synthesis actually works, why protecting groups exist, what goes wrong during a coupling cycle, why purification is the real cost center, and why scaling this 60-year-old chemistry to blockbuster-drug volumes is a genuine engineering problem.
-
Insulin: The Original Blockbuster Peptide Before GLP-1 drugs, before monoclonal antibodies, there was insulin — the first hormone deficiency ever treated with the hormone itself, the first drug purified from animal organs at industrial scale, and in 1982 the first genetically engineered drug ever approved. The molecule's two-chain structure, the 1921 discovery, the shift to recombinant production, and the amino-acid-substitution engineering behind rapid- and long-acting analogs.
-
MariTide and the Antagonist Paradox Amgen's maridebart cafraglutide blocks the same receptor tirzepatide activates, still produces close to 20% weight loss, and does it from a monthly injection instead of a weekly one — an antibody-format peptide drug with a genuinely unresolved mechanism and a real tolerability problem.
-
Melanotan and the Peptide Underground The same 1980s skin-cancer-prevention research that produced an FDA-approved drug for a rare light-sensitivity disorder also produced melanotan II — a gray-market tanning peptide whose non-selective receptor binding causes the appetite and libido effects users chase and the mole changes, priapism, and cardiac events regulators warn about.
-
Multi-Receptor Peptide Design: One Molecule, Several Targets Tirzepatide hits two receptors and retatrutide hits three, and neither is a gimmick. Here's how agonism, antagonism, and biased signaling actually work at the receptor level, and why combining several of them in one peptide became the dominant strategy in metabolic drug design.
-
Natriuretic Peptides as Diagnostics: How a Hormone Became a Blood Test BNP and NT-proBNP are two of the most ordered blood tests in emergency medicine, and both are byproducts of the same hormonal pressure-relief system the heart uses to protect itself from volume overload. How the natriuretic peptide system actually works, why cleaving one prohormone produces two clinically useful biomarkers with different behavior, what the reference ranges really mean, and why the same drug class that treats heart failure also quietly breaks one of the two tests.
-
Oral Peptide Delivery: Getting a Molecule Past the Gut Alive Peptides are built to be destroyed by digestion, which is exactly what makes swallowing them as a drug so hard. Here's why the gut is a molecular gauntlet, and how SNAC, enteric coatings, robotic capsules, and nanoparticles are each trying to beat it.
-
Peptide Hormones vs Steroid Hormones: Two Signaling Systems, Two Different Speeds Why insulin acts in seconds and cortisol takes hours to do anything at all: peptide hormones are water-soluble and stuck outside the cell, triggering a receptor cascade that amplifies an existing signal, while steroid hormones slip straight through the membrane and rewrite gene transcription directly. Two chemistries, two mechanisms, and a speed difference that isn't incidental — it's the direct consequence of solubility.
-
Petrelintide and the Amylin-Only Bet Zealand Pharma's petrelintide drops the GLP-1 component entirely and still produced 10.7% weight loss with placebo-like tolerability in its lead Phase 2 trial — a real test of whether amylin alone can compete with the incretin class, backed by a $5.3 billion Roche partnership.
-
PT-141 (Bremelanotide) and the Arousal Pathway Bremelanotide is a real, FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder — and also one of the most heavily grey-marketed peptides in circulation, sold as "PT-141" nasal sprays and vials with no prescription and no oversight. Both facts are true at once, and the gap between them is worth understanding on its own mechanistic terms.
-
Retatrutide: The Triple Agonist Pushing Past Tirzepatide Retatrutide's third receptor mechanism has produced the largest weight-loss and liver-fat numbers of any peptide therapeutic tested so far, and an eight-trial Phase 3 program to match. It also has a documented heart-rate signal the earlier drugs in its class don't carry.
-
Signal Peptides and Protein Trafficking: The Address Label Every Secreted Protein Carries Every secreted or membrane-bound protein a cell makes carries a short amino acid tag telling the ribosome where to deliver it — a discovery that won Günter Blobel the 1999 Nobel Prize. How the signal recognition particle intercepts a nascent protein mid-synthesis, docks it at the ER membrane, and how choosing the right signal peptide has become a real engineering lever in biopharmaceutical manufacturing.
-
Survodutide and Mazdutide: The Glucagon Bet Two GLP-1/glucagon dual agonists, developed an ocean apart by Boehringer Ingelheim and Innovent Biologics, are testing whether adding back a hormone that normally raises blood sugar can still produce a net metabolic win.
-
The Peptide Half-Life Problem Native peptides die in the bloodstream in minutes, chewed apart by proteases and flushed through the kidneys. Turning them into weekly or monthly drugs is a chemical-engineering exercise: lipidation and albumin binding, PEGylation and its alternatives, D-amino acid substitution, and backbone cyclization. What each trick actually does, what it costs, and how the modern blockbusters stack them.
-
What a Peptide Actually Is: The Chemistry Between an Amino Acid and a Protein Peptide, polypeptide, protein — the words get used loosely, but the underlying chemistry is precise: one repeated bond, one repeated cellular assembly line, and a size boundary that isn't just semantic. How the ribosome actually builds a peptide chain, how the body tears one back down, and why that size boundary decides whether a drug can be a pill or has to be an injection.
-
Creatine, Honestly Creatine is the most-studied supplement in sports science, and also the most mythologized — kidney damage, mandatory loading phases, and cognitive miracle claims that don't survive a close read of the meta-analyses. A mechanistic look at the phosphocreatine system as a chemical capacitor, the real effect sizes from recent meta-analyses, why some people are non-responders, and what the cognition evidence actually supports.
-
Glucose and Insulin: The Body's Control Loop Blood glucose regulation is a textbook negative-feedback control system: a narrow setpoint, two antagonistic actuators, a sensor with a measurable lag, and a failure mode that modern medicine now patches with an actual external controller. A tour of the insulin-glucagon loop, what HbA1c and continuous glucose monitors really measure, how insulin resistance degrades the actuator, and how PID and model predictive control ended up running inside an insulin pump.
-
How Pain Actually Works Pain is not a direct readout of tissue damage — it's a signal constructed and re-shaped at multiple checkpoints between the injury site and conscious awareness, any of which can be opened, closed, amplified, or fooled. A tour of nociceptors and the two fiber types that carry different pain qualities, the spinal gate that rubbing an injury actually closes, why a heart attack can feel like a sore left arm, and how chronic pain can persist as a real neurophysiological state long after the tissue that started it has healed.
-
How Vaccines Train the Immune System A vaccine doesn't fight a pathogen — it exploits a timing gap in how the adaptive immune system learns. A tour of antigen presentation, the germinal center's iterative affinity-maturation loop, why five very different vaccine platforms all converge on the same endpoint, why the mRNA platform is architecturally different from everything before it, and the honest reason some vaccines need boosters and others don't.
-
Plantar Fasciitis: Mechanics and Evidence-Based Fixes The plantar fascia is a load-bearing structural element, not an inflamed tissue — the "-itis" in plantar fasciitis is a misnomer for a degenerative fasciosis. A mechanical breakdown of the windlass mechanism, why the first steps out of bed are the worst ones, the heavy-slow-resistance protocol with actual RCT numbers behind it, and an honest evidence ladder ranking every common treatment from heel raises to magnetic insoles.
-
The Huberman Lab Peptides Episode, Reviewed: What Dr. Bakri Said and What Survives Scrutiny In June 2026, Andrew Huberman spent nearly three hours with physician Abud Bakri walking through BPC-157, GHK-Cu, epithalon, pinealon, thymosin alpha-1, GLP-1s, and retatrutide. The episode is a genuinely useful map of what people are injecting and why. It is also a case study in how conversational time can flatten a very steep evidence gradient. A peptide-by-peptide fact-check of the claims, the mechanisms, and the regulatory maze in between.
-
VO2 Max: What It Measures and Whether You Can Change It VO2 max predicts all-cause mortality better than cholesterol, blood pressure, or BMI, and it does it by testing an entire oxygen-delivery pipeline end to end rather than any single organ. A walk through the Fick equation that defines it, the lab test versus the number your watch guesses, the central-versus-peripheral split that decides where the ceiling actually sits, and what a 20-week family study reveals about how much of your trainability is genetics you can't touch.
-
How Anesthesia Works (and Why We Still Can't Fully Explain It) General anesthesia is one of the most-used interventions in medicine and one of the least understood. A tour of what anesthetics actually have to do, the receptors we can name, the network-level collapse of consciousness, how we watch a brain go under with EEG, and the honest gaps that remain.
-
The Science of Muscle Hypertrophy: Tension, Volume, and the Folklore What actually makes a muscle grow, separated from the gym mythology. The mechanotransduction-to-mTOR pathway, mechanical tension versus the metabolic stress red herring, the volume and proximity-to-failure evidence, protein intake numbers that hold up, and an honest dose-response model you can train by.
-
Diet and Cognition: What the Evidence Actually Supports, and What the Marketing Sells Most diet-and-cognition claims rest on observational studies that systematically over-promise, and the few large randomized trials that tested the headline diets came back muted. A skeptical-engineer walk through the Mediterranean and MIND data, omega-3s honestly, the supplement graveyard, and the one mechanism that actually holds up.
-
Eye Strain at the Computer What actually happens to your eyes during a long screen session — the accommodation and convergence machinery, the dry-eye mechanism behind most "strain," the real evidence for the 20-20-20 rule and blue-light glasses, and which monitor and lighting choices genuinely help.
-
The Honest Science of Hydration Where the "eight glasses a day" number actually came from (nowhere), what your kidneys are really doing, why thirst is a better controller than any daily quota, how much water comes from food and coffee, and when electrolytes matter versus when they are just flavored marketing.
-
Walking as Infrastructure for Thinking The honest case for treating walking as a cognitive tool, not just exercise: what the default-mode network and incubation literature actually show, where the Stanford creativity studies replicate and where they don't, why the "10,000 steps" target is marketing and 7,000 is the real plateau, the metabolic cost of prolonged sitting, and how to wedge walking into a desk job.
-
Exercise for Engineers: The Minimum Effective Dose The cardio, strength, and mobility numbers honestly, sourced from the dose-response literature: where the mortality curve is steep, the Zone 2 versus HIIT debate settled, the strength-training case that survived peer review, and a concrete schedule that fits a knowledge-worker week across hot, cold, dark, and polluted climates.
-
Blue Light and Circadian Rhythm Blue light has become the bogeyman of evening screen use, and the picture in the literature is messier than the marketing suggests. We walk the actual melatonin-suppression evidence, the melanopsin and ipRGC mechanism, why intensity and timing matter far more than the color filter on your phone, what Night Shift and warm front-lights genuinely do, and a calibrated take on screens before sleep.
-
Mechanical Keyboards and RSI An evidence-based read on what actually causes repetitive strain at the keyboard and what helps. Switch force curves, split and columnar layouts, the typing forces we use versus the ones we need, what the studies say versus what the enthusiast community claims, and the honest hierarchy of things that move the needle.
-
Burnout, Mechanistically Past the buzzword and the wellness fluff: what the Maslach Burnout Inventory's three dimensions actually measure, why the cortisol story is mostly myth, the job demands-resources model that the evidence actually supports, why autonomy and reward imbalance predict burnout better than hours worked, the early warning signals an engineer can self-monitor, what recovery research honestly says about vacations, and how to tell burnout from depression and from rust-out.
-
Caffeine Pharmacokinetics for Engineers How caffeine actually works inside your body: adenosine receptor antagonism, the 5-hour half-life math that explains why your 3 PM cup is still measurable at midnight, tolerance and withdrawal as receptor upregulation, CYP1A2 genetic variation, and dose-response curves for alertness versus anxiety — written for people who reason in graphs and decay equations.
-
Sleep Architecture and On-Call: The Engineer's Body on Rotating Shifts How NREM and REM sleep are organized across the night, why a 4 AM page hurts more than a 4 AM party, what sleep debt actually costs, and how to design on-call rotations and personal countermeasures that respect the biology instead of fighting it.
-
The Science of Learning for Technical Skills Why rereading and tutorial-following feel productive while teaching you almost nothing: the testing effect, the actual Ebbinghaus math behind spaced repetition, interleaving, Bjork's desirable difficulties, and what deliberate practice really means for engineers — plus an Anki workflow for certs and new stacks that survives contact with a real on-call schedule.
-
Wearable Sensor Accuracy: What Your Watch Can and Cannot Measure A measurement-engineer's reading of consumer wearables: which numbers on your watch are real signal, which are model-driven fiction, and how the underlying sensors (PPG, accelerometer, SpO2, ECG, skin temperature) actually behave under load, low perfusion, dark skin tones, and free-living conditions.
-
The Complete Guide to Stretching: Science, Technique, and Building Lasting Flexibility A deep, research-backed guide to stretching — covering the science of how flexibility actually works, the measurable health benefits, every major stretching technique, the debate between holding longer vs. more repetitions, essential stretches for every major muscle group, and how to track and measure your progress.